Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day, MBA

CEODaniel P. O'Day, MBA

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

171.69B

Market cap171.69B

Price-Earnings ratio

-52.09

Price-Earnings ratio-52.09

Dividend yield

2.57%

Dividend yield2.57%

Average volume

7.28M

Average volume7.28M

High today

$138.46

High today$138.46

Low today

$135.91

Low today$135.91

Open price

$136.81

Open price$136.81

Volume

3.41M

Volume3.41M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$108.46

52 Week low$108.46

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $138.20. The company's market cap stands at 171.69B, with a P/E ratio of -52.09 and a dividend yield of 2.57%.

As of 2026-08-16, Gilead Sciences(GILD) stock has fluctuated between $135.91 and $138.46. The current price stands at $138.20, placing the stock +1.7% above today's low and -0.2% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 3.41M, against a daily average of 7.28M.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

GILD News

Simply Wall St 1d

Gilead Sciences Could Be 8% Overvalued As AI Deal And Q2 Results Lift Shares

Gilead Sciences (GILD) is back on investors’ radar after its new collaboration with Nucleai, which applies AI powered tissue analytics to antibody drug conjugat...

MarketWatch 3d

Your prescription drugs shouldn’t cost more than your mortgage. Inside the broken math that got us here.

For many Americans, the price of prescription drugs is an enigma. One medication costs a few dollars, while another costs more than a mortgage. Running a pharm...

Simply Wall St 3d

Gilead Sciences Starts AI Biomarker Research Partnership For Oncology

Gilead Sciences (NasdaqGS:GILD) announced a new AI powered translational research collaboration with Nucleai focused on biomarker discovery and precision oncolo...

Analyst ratings

80%

of 30 ratings

Buy

80%

Hold

20%

Sell

More GILD News

TipRanks 5d

Lakefront Biotherapeutics Boosts Immunology Push With Ouro Deal and Strong Cash Outlook

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.